PA
KNSA icon

PharVision Advisers’s Kiniksa Pharmaceuticals KNSA Stock Holding History

PharVision Advisers’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,722
Closed -$261K – 856
2025
Q3 		$261K Buy
+6,722
New +$218K 0.15% 306

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

PharVision Advisers's KNSA Position: Q4 2025 in Review

PharVision Advisers sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2025, closing a stake of 6,722 shares — an estimated $261K sold.

PharVision Advisers first reported a position in KNSA in Q3 2025 and held it in 1 quarter. The position peaked at $261K in Q3 2025. 224 funds tracked by Wall St. Rank hold KNSA as of Q4 2025.

  • PharVision Advisers reported no remaining Kiniksa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 6,722 Kiniksa Pharmaceuticals shares in Q4 2025, an estimated $261K.
  • PharVision Advisers first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Kiniksa Pharmaceuticals position peaked at $261K in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.